Equities research analysts at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
The stock’s 50 day moving average price is $0.03 and its 200-day moving average price is $0.05. The firm has a market cap of $10,000.00, a PE ratio of 0.00 and a beta of 0.76. Navidea Biopharmaceuticals has a 52-week low of $0.00 and a 52-week high of $0.17.
About Navidea Biopharmaceuticals
Read More
- Five stocks we like better than Navidea Biopharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- Buffett Bails on BYD: What It Means for the Future of EV Stocks
- 3 Warren Buffett Stocks to Buy Now
- Domino’s vs. Papa John’s: Stock Showdown of Pizza Giants
- Stock Analyst Ratings and Canadian Analyst Ratings
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.